The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) was $21.59 for the day, up 2.81% from the previous closing price of $21.0. In other words, the price has increased by $2.81 from its previous closing price. On the day, 1.83 million shares were traded. APLS stock price reached its highest trading level at $21.71 during the session, while it also had its lowest trading level at $20.9.
Ratios:
Our analysis of APLS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.68 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 34.74. For the most recent quarter (mrq), Quick Ratio is recorded 3.10 and its Current Ratio is at 3.54. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 0.93.
On October 15, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $32.
Goldman Downgraded its Neutral to Sell on September 26, 2025, while the target price for the stock was maintained at $18.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 17 ’25 when Watson David O. sold 5,000 shares for $20.06 per share. The transaction valued at 100,300 led to the insider holds 108,730 shares of the business.
Watson David O. bought 5,000 shares of APLS for $100,300 on Nov 17 ’25. On Oct 21 ’25, another insider, Sullivan Timothy Eugene, who serves as the Chief Financial Officer of the company, sold 10,000 shares for $28.03 each. As a result, the insider received 280,300 and left with 110,936 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 2731679488 and an Enterprise Value of 2726821376. As of this moment, Apellis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 72.72. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.11. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.69 while its Price-to-Book (P/B) ratio in mrq is 6.81. Its current Enterprise Value per Revenue stands at 2.683 whereas that against EBITDA is 33.22.
Stock Price History:
The Beta on a monthly basis for APLS is 0.36, which has changed by -0.36368996 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, APLS has reached a high of $35.72, while it has fallen to a 52-week low of $16.10. The 50-Day Moving Average of the stock is -6.50%, while the 200-Day Moving Average is calculated to be -2.57%.
Shares Statistics:
APLS traded an average of 2.56M shares per day over the past three months and 2384830 shares per day over the past ten days. A total of 126.50M shares are outstanding, with a floating share count of 103.76M. Insiders hold about 17.99% of the company’s shares, while institutions hold 99.35% stake in the company. Shares short for APLS as of 1763078400 were 16349387 with a Short Ratio of 6.38, compared to 1760486400 on 18061349. Therefore, it implies a Short% of Shares Outstanding of 16349387 and a Short% of Float of 17.01.
Earnings Estimates
The firm’s stock currently is rated by 11.0 analysts. The consensus estimate for the next quarter is -$0.52, with high estimates of -$0.37 and low estimates of -$0.63.
Analysts are recommending an EPS of between $0.48 and $0.04 for the fiscal current year, implying an average EPS of $0.27. EPS for the following year is -$1.15, with 11.0 analysts recommending between -$0.09 and -$1.73.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 18 analysts. It ranges from a high estimate of $232.4M to a low estimate of $184.6M. As of. The current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $212.53MFor the next quarter, 18 analysts are estimating revenue of $193.29M. There is a high estimate of $208.5M for the next quarter, whereas the lowest estimate is $174M.
A total of 19 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $1.05B, while the lowest revenue estimate was $698.26M, resulting in an average revenue estimate of $990.98M. In the same quarter a year ago, actual revenue was $781.37MBased on 19 analysts’ estimates, the company’s revenue will be $871.07M in the next fiscal year. The high estimate is $955M and the low estimate is $787.62M.
